Roberts Jason A, Hobday Linda K, Ibrahim Aishah, Aitken Thomas, Thorley Bruce R
National Enterovirus Reference Laboratory, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, 792 Elizabeth St, Melbourne 3000, Victoria, Australia.
Commun Dis Intell (2018). 2020 Apr 15;44. doi: 10.33321/cdi.2020.44.24.
Australia conducts surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years as recommended by the World Health Organization (WHO) as the main method to monitor its polio-free status. Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2015, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.2 non-polio AFP cases per 100,000 children, meeting the WHO performance criterion for a sensitive surveillance system. Two non-polio enteroviruses, enterovirus A71 and coxsackievirus B3, were identified from clinical specimens collected from AFP cases. Australia complements the clinical surveillance program with enterovirus and environmental surveillance for poliovirus. Two Sabin-like polioviruses were isolated from sewage collected in Melbourne in 2015, which would have been imported from a country that uses the oral polio vaccine. The global eradication of wild poliovirus type 2 was certified in 2015 and Sabin poliovirus type 2 will be withdrawn from oral polio vaccine in April 2016. Laboratory containment of all remaining wild and vaccine strains of poliovirus type 2 will occur in 2016 and the National Enterovirus Reference Laboratory was designated as a polio essential facility. Globally, in 2015, 74 cases of polio were reported, only in the two remaining countries endemic for wild poliovirus: Afghanistan and Pakistan. This is the lowest number reported since the global polio eradication program was initiated.
澳大利亚按照世界卫生组织(WHO)的建议,对15岁以下儿童的急性弛缓性麻痹(AFP)病例进行监测,作为监测其无脊髓灰质炎状态的主要方法。儿童AFP病例会通报给澳大利亚儿科监测部门或儿科主动强化疾病监测系统,粪便样本会被送往国家肠道病毒参考实验室进行病毒学调查。2015年,临床监测未报告脊髓灰质炎病例,澳大利亚报告每10万名儿童中有1.2例非脊髓灰质炎AFP病例,达到了WHO对敏感监测系统的绩效标准。从AFP病例采集的临床样本中鉴定出两种非脊髓灰质炎肠道病毒,肠道病毒A71和柯萨奇病毒B3。澳大利亚通过肠道病毒和脊髓灰质炎病毒环境监测对临床监测计划进行补充。2015年从墨尔本采集的污水中分离出两种类似萨宾株的脊髓灰质炎病毒,这些病毒可能是从使用口服脊髓灰质炎疫苗的国家输入的。2型野生脊髓灰质炎病毒于2015年获得全球根除认证,2型萨宾脊髓灰质炎病毒将于2016年4月从口服脊髓灰质炎疫苗中撤出。2016年将对所有剩余的2型野生和疫苗株脊髓灰质炎病毒进行实验室封存,国家肠道病毒参考实验室被指定为脊髓灰质炎关键设施。2015年全球报告了74例脊髓灰质炎病例,仅在野生脊髓灰质炎病毒仍然流行的两个国家:阿富汗和巴基斯坦。这是全球脊髓灰质炎根除计划启动以来报告的最低病例数。